BB Biotech AG (XSWX:BION) Net Income: CHF797.7 Mil (TTM As of Mar. 2026)


XSWX:BION BB Biotech AG XSWX:BION
32 GF Score
Price CHF51.90
! 4 Warning Signs
View Full Analysis

What is BB Biotech AG Net Income?

BB Biotech AG XSWX:BION +3.80% 32 Net Income is CHF797.7 Mil as of Mar. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. BB Biotech AG's Net Income for the three months ended in Mar. 2026 was CHF-21.4 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was CHF797.7 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. BB Biotech AG's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was CHF-0.39.


BB Biotech AG  (XSWX:BION) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

BB Biotech AG's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BB Biotech AG Net Income Related Terms


BB Biotech AG Net Income Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Net Income Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -404.81 -357.81 -206.61 75.90 578.13

BB Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -240.93 -100.24 447.62 471.69 -21.38
XSWX:BION
32GF Score
BB Biotech AG XSWX:BION
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

BB Biotech AG's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=578.199+-0.066+0+1.1368683772162E-13
=578.1

BB Biotech AG's Net Income for the quarter that ended in Mar. 2026 is calculated as

Net Income(Q: Mar. 2026 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-21.357+-0.02+0+0
=-21.4

Net Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF797.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of CHF797.7 Mil mean?
BB Biotech AG (XSWX:BION) has a Net Income of CHF797.7 Mil as of Mar. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on BB Biotech AG and its competitors.
Is BB Biotech AG's Net Income too high?
BB Biotech AG's current Net Income is CHF797.7 Mil. Overall, BB Biotech AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Net Income compare to VRTX and REGN?
BB Biotech AG's Net Income of CHF797.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current Net Income is CHF797.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Net Income of CHF797.7 Mil. The current Net Income is CHF797.7 Mil. BB Biotech AG's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Net Income is CHF797.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
32GF Score

Get the complete analysis for XSWX:BION

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.90
Price